2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2940

Bechet’s Disease and Sleep Quality in Korean Patients
Abstract Number: 2941

Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients
Abstract Number: 2942

Sequencing of 16S rRNA Reveals a Distinct Salivary Microbiome Signature in Behcet’s Disease
Abstract Number: 2943

Relationship Between Menstruation and Symptoms of Behcet’s Syndrome
Abstract Number: 2944

Use of Muscle Biopsies for the Diagnosis of Systemic Vasculitis in a Rheumatology Service
Abstract Number: 2945

Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”
Abstract Number: 2946

Large Scale Genetic Analysis in BehçEt Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci
Abstract Number: 2947

Adalimumab Versus Infliximab in Cystoid Macular Edema of Uveitis Associated to BehçEt Disease. Multicenter Study of 34 Patients
Abstract Number: 2948

Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behçet’s Syndrome Patients with Gastrointestinal Involvement: A Controlled Study
Abstract Number: 2949

Surgical Method for Aortic Root Involvement of Behcet Disease
Abstract Number: 2950

Cogan Syndrome: Treatment and Outcome from French Nationwide Retrospective Study and Literature Review of 62 Patients
Abstract Number: 2951

Patient Outcomes in Primary Angiitis of the Central Nervous System
Abstract Number: 2952

Differentiation Between Neurosarcoidosis and Primary CNS Vasculitis Based on Clinical and Cerebrospinal Fluid Parameters
Abstract Number: 2953

Comparison of Patient Outcomes in Primary Angiitis of the Central Nervous System and Reversible Cerebral Vasoconstriction Syndrome
Abstract Number: 2954

Anti-IL6-R Tocilizumab in Refractory Uveitis Associated with BehçEt’s Disease. Multicenter Study of 11 Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].